Glenmark has recently launched Remogliflozin- a novel SGLT2 inhibitor- and India is the first country to get access to this innovative drug. Remogliflozin has been studied in 26 clinical trials globally , covering about 2,500 patients from various ethnicities. Phase III clinical trials are the best way to find a new paradigm for treatment and change the way how doctors treat patients. Glenmark invites you for an interactive webinar on 15th May 2019 from 9:30 pm onwards. In this webinar, Dr.
Hemant P. Thacker and Dr. Mahesh K. Shah will talk about the "Indian Experience Of Remogliflozin- Phase III Clinical Study" . We invite you to submit your questions which will be answered by the speakers at the end of the session.
